Gentian Diagnostics ASA: Fourth quarter and full year 2023 report

09. Feb 2024 | 3 min read

Moss, 9 February 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the fourth quarter and full year 2023.


  • Sales of MNOK 37.5 in 4Q23, up 34% vs 4Q22 (23% organic growth). Full year sales of MNOK 135.2 in 2023, up 33% vs 2022 (21% organic growth)
  • EBITDA of NOK -1.0 million in 4Q23 versus NOK -1.5 million in 4Q22. Irregularities related to raw materials resulted in an increased COGS estimated to NOK 1.8 million in 4Q23. EBITDA for the full year 2023 of NOK 3.3 million, compared to NOK -13.0 million in 2022
  • Year-end cash position at NOK 87.6 million, up NOK 6.0 million compared to year-end 2022
  • Cystatin C sales increased 49% in 4Q23 compared to 4Q22 and 41% in 2023 vs 2022
  • Third party sales increased 96% in 4Q23 compared to 4Q22 and 67% in 2023 vs 2022
  • Optimisation of the NT-proBNP prototype continues with noteworthy progress in 4Q23 and preparations for production scalability experiments were initiated

GDASA Interim report 4Q 2023

GDASA Q4 23 presentation



Gentian’s CEO Hilja Ibert and CFO Njaal Kind will present the results today at 09.00 am, followed by a Q&A session. Join the webcast and submit questions via the following link:

The webcast will be available on the company website after the presentation.


IR contact:

Njaal Kind, CFO and COO
+47 919 06 525 (mobile)


This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian Diagnostics ASA, on 9 February 2024 at 08:00 CET.


About Gentian

Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit



You may also read

Jan 30, 2024 - Ole Sørlie

Invitation to presentation of fourth quarter results

Gentian Diagnostics ASA will present its fourth quarter 2023 results on February 9th at 09.00 am.

Dec 19, 2023 - Kristin Hart

Disclosure of shareholding

Viola AS, a wholly-owned subsidiary of Rasmussengruppen AS, acquired 150,000 shares in Gentian Diagnostics..